ArticleJournal of health economics and outcomes research2025

Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir Compared with Molnupiravir in Patients at High Risk for Progression to Severe COVID-19 in Japan.

Akira Yuasa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.